Adult vaccine demand is shifting toward a more year-round pattern
September 2026
Adult vaccine demand is increasingly diffusing across the full calendar year rather than concentrating in the traditional fall and winter respiratory seasons. Historically, adult vaccine demand peaked sharply in Q4; however, those Q4 peaks are now flattening as demand levels out across quarters (Figure 1). A key driver of this shift appears to be the growing contribution of medical claims relative to retail (pharmacy) claims, which is distributing vaccination opportunities more evenly throughout the year.
This year-round diffusion is why Vaccine Track is moving to a biannual report cadence organized around respiratory and non-respiratory seasons. To enable consistent comparisons across these different vaccination patterns, this report groups Q4 of one calendar year with Q1 of the following year as a single respiratory season, and Q2–Q3 as the non-respiratory season. Annual calendar-year trends are also presented to provide longer-term context.
RSV Demand Fell Overall This Past Respiratory Season, but Rose Among Adults Aged 50-64
RSV volume grew among adults aged 50-64 years, likely reflecting the ACIP’s April 2025 expanded recommendation for high-risk adults in this age group. Conversely, RSV volume fell among adults aged ≥65 years, who were recommended for RSV vaccination earlier. Season-over-season, RSV volume fell among all adults aged ≥19 years, with the steepest drops among the oldest adults. Among patients aged ≥75 years, volume fell ~51% between the past two respiratory seasons, while among patients 65–74 years volume fell ~42%. The 50–64-year age group showed an opposite trend, with volume increasing ~26%. The 19–49-year age group stayed roughly flat across seasons (Figure 2).
The public health implications are important to consider, as lower adult RSV vaccination may leave more individuals susceptible during respiratory season and could contribute to a greater burden of disease.
Among U.S. adults 60+, RSV is associated with an estimated 4 million annual cases and $6.6 billion in yearly costs, with just 4% of cases requiring hospitalization but driving 94% of direct medical costs. For scale, total RSV volume fell 42% between 2024 and 2025 (10,856,749 to 6,286,359). Importantly, claims volume alone cannot determine whether observed patterns reflect gaps in protection or the fact that many eligible older adults have already received RSV vaccination. To help address this limitation, Vaccine Track plans to incorporate vaccination coverage rate (VCR) insights in future analyses, providing a more complete understanding of vaccine uptake and population protection.
Hepatitis B Volume Continues to Grow, Though Growth is Slowing
Hepatitis B (HepB), a non-seasonal vaccine, grew across every measure this past year: respiratory-season volume rose ~10% year-over-year (from 1,575,000 to 1,735,000 claims) and non-respiratory-season volume rose ~9% (from ~1,705,000 to ~1,860,000 claims; Figure 3). While the annual volume of HepB has grown every year since 2022, each year’s increase has been smaller than the last: +66% in 2023, +29% in 2024, and +13% in 2025 (Figure 3).
HepB may be benefiting from continued identification of unvaccinated eligible adults, along with changes to immunization measurement and a broader push on catch-up vaccination, both of which could sustain growth for a time. Further, HepB is a lifetime vaccination series; therefore, catching up more adults would likely drive lower volume over time.
While RSV is not an annual seasonal vaccine, uptake is strongly concentrated around the respiratory season, and literature suggests gaps in public understanding of RSV and its seasonality. In contrast, non-seasonal vaccines, particularly HepB, continue to increase in volume.
Retail Drives the Season’s Decline; Medical Holds Steady
Total claims volume for the most recent respiratory season was lower than the previous season. For all vaccines excluding flu, retail claims volume decreased ~12% between the past two respiratory seasons, while medical claims volume fell less than 1% (Figure 4A).
Outside of respiratory season, the picture looks different. Non-respiratory season volume grew ~6% year-over-year (~33.1 million claims in 2024 to ~35.2 million in 2025). This growth was concentrated almost entirely in the medical setting, while retail held steady.
This divergence — a softening respiratory season alongside a strengthening off-season — suggests demand for non-seasonal vaccines is becoming less tied to seasonal timing, potentially reflecting catch-up dosing or shifting patient behavior in medical settings. Age-stratified analyses reveal important differences underlying this overall pattern.
In the medical setting, growth was concentrated among adults ages 50-64, whose volume rose ~12% between the 24/25 respiratory season and the 25/26 respiratory season, even as volume among adults 65-74 and 75+ declined ~17% and ~11%, respectively (Figure 4B).
The retail decline was even more age-driven: volume among adults 65-74 and 75+ fell ~18% and ~25%, respectively, season-over-season, while volume among adults under 65 held roughly flat in both settings (Figure 4C). Whether the respiratory season decline continues into 2026 will depend on whether that seasonal channel recovers or the off-season trend continues to offset it.
The Season-Over-Season Decline Is Concentrated Among White Adults
Across past respiratory seasons, the sharpest declines are concentrated among White adults, a pattern visible across pneumococcal, RSV, Tdap, and zoster vaccines. Comparing the 2024/2025 respiratory season against the 2025/2026 respiratory season, claims volume fell most steeply among White adults (12% decrease; Figure 5A), while volume among Hispanic, Black, and Asian-Other adults moved comparatively less (5-11% decrease; Figure 5B).
The recent decline may partly reflect the tail end of a one-time surge in 2023 – a pattern that is visible across all racial groups, though most pronounced among White adults. Annual volume rose across every group in 2023 (27-45%), then pulled back through 2024 and 2025. White adults had both the largest 2023 surge and the steepest reversal, falling ~23% from the 2023 peak, though 2025 volume remained ~12% above the 2022 starting point (Figure 5C). Other groups saw milder versions of the same pattern, with 2025 volume ending 19-22% above 2022 (Figure 5D). This suggests the decline among White adults described above is partly a reversion from a 2023 increase rather than an entirely new drop in coverage, though this applies less to adults among other racial groups.
Note: Patients with unmatched race data or with a race/ethnicity classified as Unspecified are not presented.
It is possible that earlier uptake among White adults pulled demand forward, leaving fewer unvaccinated patients later on. Additionally, possible messaging fatigue or lower perceived urgency among this previously high-uptake group may be at play.
About Vaccine Track
Vaccine Track measures adult vaccinations through claims data.
Vaccine Track measures adult vaccinations through claims data for all adults ages ≥19, including hepatitis A, hepatitis B, tetanus-diphtheria (Td), tetanus-diphtheria-pertussis (Tdap), shingles, pneumococcal, influenza (flu) and respiratory syncytial virus (RSV).
While flu vaccination claims are included in the interactive data tools, they are typically not included in Vaccine Track insights due to their strong seasonality and the availability of robust analyses of flu vaccination trends provided by the CDC. RSV vaccination claims are similarly excluded from overall adult claims analyses due to their association with the respiratory virus season.
Not all vaccines are indicated or recommended for all adults, and the inclusion of the full adult data set should not be interpreted as promoting or endorsing the use of any vaccine beyond its FDA-approved indication(s) or CDC recommendations.
Vaccine Track provides race/ethnicity data stratification. Race/ethnicity data are self-reported and may not be available for all people who received a vaccination. This data may not be representative of the entire US population.